Our clinical investigations demonstrate, that nonmyeloablative stem cell transplantation (NST) is a novel therapeutic option in patients with high-risk ALL or AML. NST can be administered to patients eligible for allogeneic stem cell transplantation with contraindications against high-dose radio- and chemotherapy (standard SCT). After NST, infections and late onset acute graft-versus-host disease (GvHD) frequently occurred, but transplant-related mortality was low in contrast to standard SCT. Leukemia-free survival and overall survival were similar after NST and standard SCT. A higher relapse rate after NST was balanced by a higher transplant-related mortality after standard SCT. The conditioning regimen itself had no relevant impact on survival. Sequential chimerism analyses of leukocyte subpopulations resulted in early diagnosis of mixed chimerism, which proved to be predictive for later relapses. Stable mixed chimerism was not established in these patients. Adoptive immunotherapy in patients, ...
Johan Törlén, Olle Ringdén, Jennifer Le Rademacher, Minoo Batiwalla, Junfang Chen, Tom Erkers, Vincent Ho, Partow Kebriaei, Carolyn Keever-Taylor, Tamila Kindwall-Keller, Hillard M. Lazarus, Mary J. Laughlin, Michael Lill, Tracey OBrien, Miguel Angel Perales, Vanderson Rocha, Bipin N. Savani, David Szwajcer, David Valcarcel, Mary Eapen ...
Wiskott-Aldrich syndrome (WAS) is an inherited immunodeficiency caused by mutations in the gene encoding WASP that is treated with hematopoietic stem/progenitor cell (HSPC) transplantation. Infusion of autologous HSPCs modified ex vivo by gene therapy is an alternative approach when matched donors are unavailable. Following reduced-intensity conditioning regimen, three WAS patients were infused with autologous HSPCs genetically corrected by […]. ...
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched BMT to the use of such donors, investigating up to several postgrafting immunosuppression regimens that incorporate high-dose Cy. Of central interest is the incorporation of sirolimus into this postgrafting immunosuppression regimen. The primary goal is to identify a transplant regimen associated with acceptable rates of severe acute GVHD and NRM by Day 100 ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
The study aimed to evaluate the impact of myeloablative (MAC) versus reduced intensity conditioning (RIC) regimen on allo-HSCT outcomes in patients with t-AML
TY - JOUR. T1 - Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. AU - Madden, Lisa M.. AU - Hayashi, Robert J.. AU - Chan, Ka Wah. AU - Pulsipher, Michael A.. AU - Douglas, Dorothea. AU - Hale, Gregory A.. AU - Chaudhury, Sonali. AU - Haut, Paul. AU - Kasow, Kimberly A.. AU - Gilman, Andrew L.. AU - Murray, Lisa M.. AU - Shenoy, Shalini. PY - 2016/8/1. Y1 - 2016/8/1. N2 - Reduced-intensity conditioning (RIC) before hematopoietic stem cell transplantation (HCT) in children could result in fewer complications during follow-up compared with myeloablative regimens. Hence, many RIC regimens are under investigation, but long-term follow-up is essential. We describe late follow-up beyond 2 years post-HCT in 43 children with nonmalignant disorders who underwent related or unrelated donor (56%) HCT on a multicenter study using a RIC regimen (alemtuzumab, fludarabine, and melphalan) followed by bone marrow (n = 30), peripheral ...
BM failure (BMF) is a major and frequent complication of dyskeratosis congenita (DKC). Allogeneic hematopoietic SCT (allo-HSCT) represents the only curative treatment for BMF associated with this condition. Transplant-related morbidity-mortality is common especially after myeloablative conditioning regimens. Herein, we report nine cases of patients with DKC who received an allo-SCT at five different member centers within the Eastern Mediterranean Blood and Marrow Transplantation Registry. Between October 1992 and February 2011, nine DKC patients (male, 7 and female, 2), with a median age at transplantation of 19.1 (4.9-31.1) years, underwent an allo-HSCT from HLA-matched, morphologically normal-related donors (100percent). Preparative regimens varied according to different centers, but was reduced intensity conditioning (RIC) in eight patients. Graft source was unstimulated BM in five cases (56percent) and G-CSF-mobilized PBSCs in four (44percent) cases. The median stem cell dose was 6.79 ...
ContextA minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematolo
In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with a human leukocyte antigen (HLA)-identical sibling donor were analyzed according to 2 types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high-dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (hazard ratio [HR], 1.64; 95% confidence interval [95% CI], 1.2-2.2; P = .001), but the 3-year nonrelapse mortality (NRM) rate was decreased in the RIC group (HR, 0.61; 95% CI, 0.41-0.91; P = .015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SMC vs 33% in RIC; multivariate P = .9; and 45% vs 41%, respectively; P = .8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age > 50 years in 73% RIC vs 28% in SMC, P < .001) and ...
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic ...
The initial trials of reduced intensity allogeneic hematopoietic cell transplantation regimens for metastatic renal cell carcinoma have generated considerable interest because responses were observed in patients who had experienced progressive disease after conventional immunotherapy (13, 14, 15 , 17 , 18) , and some of these responses have been durable for ,4 years (46) . However, despite the use of reduced intensity conditioning regimens, the management of conditioning-related toxicity generally required inpatient care, and treatment-related complications have been responsible for deaths in 11 to 33% of patients treated in this fashion (13, 14, 15, 16, 17 , 47) . The low toxicity of the fludarabine/total body irradiation conditioning regimen combined with posttransplant cyclosporine/mycophenolate mofetil has been established in patients with hematologic malignancies (12 , 21 , 23) . This study confirms the limited toxicity of this conditioning regimen in patients with metastatic renal cell ...
Abstract. BACKGROUND: Chronic GVHD is a major determinant of quality of life after allogeneic HCT. Systemic immunosuppressants (IS) are the mainstay of treatme
To test the safety, and efficacy of Fludarabin and TBI combination for myeloablative conditioning for elderly patients with hematological malignancies (phase
Complete title: A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus combined with MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis after HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation using Nonmyeloablative or Reduced Intensity Conditioning for Patients with Hematologic Malignancies: A Multi-Center ...
Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future
TY - JOUR. T1 - Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. AU - Busca, Alessandro. AU - Locatelli, F.. AU - Barbui, A.. AU - Ghisetti, V.. AU - Cirillo, D.. AU - Serra, R.. AU - Audisio, E.. AU - Falda, M.. PY - 2003/9. Y1 - 2003/9. N2 - Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. Whether this approach is associated with reduced risk of infectious complications is unclear. The aim of the current study was to evaluate the infectious complications in a series of 32 consecutive adult patients who received NSTat our institution. Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. Neutropenia developed in two-thirds of patients and lasted 16 days. ...
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.. ...
Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs ...
TY - JOUR. T1 - Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children. T2 - A single institution experience. AU - Hoepfner, S.. AU - Haut, Paul. AU - OGorman, M.. AU - Kletzel, M.. PY - 2003/2. Y1 - 2003/2. N2 - In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4 + cells was below normal up to 6 months post-transplant, ...
TY - JOUR. T1 - Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. AU - Ono, Yukako. AU - Mori, Takehiko. AU - Kato, Jun. AU - Yamane, Akiko. AU - Shimizu, Takayuki. AU - Kikuchi, Taku. AU - Kohashi, Sumiko. AU - Okamoto, Shinichiro. PY - 2012/9. Y1 - 2012/9. UR - http://www.scopus.com/inward/record.url?scp=84865355006&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84865355006&partnerID=8YFLogxK. U2 - 10.1002/ajh.23261. DO - 10.1002/ajh.23261. M3 - Article. C2 - 22674621. AN - SCOPUS:84865355006. VL - 87. SP - 929. EP - 931. JO - American Journal of Hematology. JF - American Journal of Hematology. SN - 0361-8609. IS - 9. ER - ...
The purpose of this study is to evaluate the outcome of imatinib combined with reduced-intensity allogeneic hematopoietic stem cell transplantation versus
TY - JOUR. T1 - Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. AU - Muramatsu, Hideki. AU - Sakaguchi, Hirotoshi. AU - Taga, Takashi. AU - Tabuchi, Ken. AU - Adachi, Souichi. AU - Inoue, Masami. AU - Kitoh, Toshiyuki. AU - Suminoe, Aiko. AU - Yabe, Hiromasa. AU - Azuma, Eichi. AU - Shioda, Yoko. AU - Ogawa, Atsushi. AU - Kinoshita, Akitoshi. AU - Kigasawa, Hisato. AU - Osugi, Yuko. AU - Koike, Kazutoshi. AU - Kawa, Keisei. AU - Kato, Koji. AU - Atsuta, Yoshiko. AU - Kudo, Kazuko. PY - 2014/5. Y1 - 2014/5. N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a ...
Ringden, O.; Labopin, M.; Schmid, C.; Sadeghi, B.; Polge, E.; Tischer, J.; Ganser, A.; Michallet, M.; Kanz, L.; Schwerdtfeger, R.; Nagler, A.; Mohty, M. (2016): Sequential chemotherapy followed by reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia (AML): a survey from the Acute Leukemia Working Party of EBMT. In: Bone Marrow Transplantation, Vol. 51: S476-S477 ...
After autologous hematopoietic cell transplantation (HCT) in the first complete remission (CR1), patients with acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in the second complete remission (CR2). The aim of this study was to analyze the outcome of allogeneic HCT performed in CR2 comparing patients with prior consolidation by autologous HCT versus patients with chemotherapy consolidation. Included were 2619 adults with allogeneic HCT in CR2 from 2000 to 2017 with (n = 417) or without (n = 2202) prior autologous HCT. Patient groups were not entirely comparable; patients with prior autologous HCT were younger, had less often a favorable cytogenetic profile, had more commonly donors other than matched siblings, and more often received reduced-intensity conditioning. In multivariate analysis, nonrelapse mortality risks in patients with prior autologous HCT were 1.34 (1.07 to 1.67; P =.01) after adjustment for age, cytogenetic risk, transplant year, donor, conditioning ...
This trial will evaluate the efficacy and the safety of a strategy of allogeneic stem cell transplantation including Rituximab in the conditioning regim
Transforming growth factor β-1, encoded by the TGFB1 gene, is a cytokine that plays a central role in many physiologic and pathogenic processes. We have sequenced TGFB1 regulatory region and assigned allelic genotypes in a large cohort of hematopoietic stem cell transplantation patients and donors. In this study we analyzed 522 unrelated donor-patient pairs and examined the combined effect of all the common polymorphisms in this genomic region. In univariate analysis, we found that patients carrying a specific allele, p001, showed significantly reduced overall survival (5-year overall survival 30.7% for p001/p001 patients vs 41.6% others; p=0.032) and increased non-relapse mortality (1-year non-relapse mortality: 39.0% vs 25.4%; p=0.039) after transplantation. In multivariate analysis, the presence of a p001/p001 genotype in patients was confirmed as an independent factor for reduced overall survival (hazard ratio=1.53 [1.04-2.24]; p=0.031), and increased non-relapse mortality (hazard ...
Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) offers curative potential to a number of older patients with acute myeloid leukemia (AML) in their first complete remission. However, there are limited data in the literature concerning post-HCT outcomes for older patients in their second complete remission (CR2). METHODS: The purpose of the current study was to retrospectively investigate within the Center for International Blood and Marrow Transplant Research database parameters influencing posttransplant outcomes for patients 60 years of age or older undergoing HCT for AML in CR2. RESULTS: In total, 196 patients from 78 centers were identified; the median age was 64 years (range, 60-78 years). Seventy-one percent had a Karnofsky performance status ≥ 90 at the time of HCT. Reduced-intensity conditioning regimens were used in 159 patients (81%). A univariate analysis demonstrated a 3-year overall survival (OS) rate of 42% (95% confidence interval [CI], 35%-49%), a leukemia-free ...
Looking for hematopoietic cell transplantation? Find out information about hematopoietic cell transplantation. The artificial removal of part of an organism and its replacement in the body of the same or of a different individual. To remove a plant from one location... Explanation of hematopoietic cell transplantation
Twenty-three leukaemia patients with a median age of 41 years (range 21-64) were enrolled into and treated on this trial from sites in Canada, Belgium, Germany and the United Kingdom. Patients were eligible for an allogeneic hematopoietic stem cell transplantation (HSCT) but could not find a matching donor in time. Sixteen patients had acute myeloid leukaemia (AML) and seven had acute lymphoblastic leukaemia (ALL). Patients were either in first or second complete remission at the time of the HSCT and the majority of patients (57%) had a poor prognosis based on their disease risk index and cytogenetic profile. A myeloablative conditioning regimen was used and (haploidentical) donor grafts were depleted of T-cells (CD34+ selection) prior to transplantation. Patients engrafted rapidly (median 12 days) and ATIR101™ was subsequently infused at a fixed dose of 2×106 CD3+ cells/kg at a median of 28 days post-transplant.. The median follow-up, on March 24, 2016, was 414 days (range 110 - 742) ...
The chemotherapy or irradiation given immediately prior to a transplant is called the conditioning or preparative regimen. The purpose is to help eradicate the patients disease prior to the infusion of HSC and to suppress immune reactions. Chemotherapy drugs and radiation both damage DNA in the cell nucleus which kills rapidly dividing cells by triggering a self-destruct mechanism called apoptosis. Bone marrow cells divide frequently and are particularly sensitive to this treatment. The bone marrow can be ablated at doses that cause minimal injury to other tissues. In allogeneic transplants a combination of cyclophosphamide with busulfan or total body irradiation is commonly employed. This treatment also has an immunosuppressive effect which prevents rejection of the HSC by the recipients immune system. Autologous transplants may also use these conditioning regimens but many other chemotherapy combinations can be used depending on the type of disease. Non-myeloablative allogeneic HSCT is a ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Burroughs LM, ODonnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG et al.. 2008. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(11):1279-87. Abstract ...
The Pretransplantation Assessment of Mortality (PAM) score is a risk score for mortality after allogeneic hematopoietic SCT (HSCT). Ethnicity is a genetically determined factor that correlated with immune-mediated outcomes of allogeneic HSCT. We evaluated the predictive value of the PAM score for transplant outcome in 276 Japanese populations in which transplant-related complications occur less frequently than Caucasians. The PAM score effectively risk-stratified these patients for survival; overall survival (OS) at 2 years was 100%, 80.2%, 49.4%, and 13.9% in the categories 1, 2, 3, and 4, respectively, showing a clear distinction of OS by categories (P|0.001). In addition, the PAM score is useful for the prediction of transplant outcomes both in patients with standard-risk underlying diseases and those with high-risk diseases. The PAM score developed in Caucasian populations is thus useful in non-Caucasian populations.
Abstract. Introduction: Early response rates to non-myeloablative therapy are encouraging, however long term remissions remain elusive. Manipulating donor lymp
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologi
Tutti i diritti riservati - Editore del portale www.youmed.it, www.youmed.tv: New Business Promotion S.r.l., Via Formentini 4/6, 20121 Milano P. Iva e Cod. fisc.: 11654240156 Tel. 02- ...
The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant procedure. The purpose of the preparative regimen is twofold:To provide adequate immunosuppression to prevent rejection of the transplanted graftTo era
For patients with advanced disease, the challenge is two-fold: Since older patients will be prepared for transplantation with RIC regimens, providing a less cytotoxic component and a lesser debulking effect than is achievable with high-intensity conditioning regimen, it appears advisable (although no controlled data exist) to use debulking therapy before transplantation. Several retrospective analyses have attempted to determine the impact of pre-transplant therapy, particularly with HMAs. It is premature to draw firm conclusions, again, because no controlled studies are available. Clinical wisdom, however, holds that a debulking attempt is indicated in patients with 5% myeloblasts or more who are heading for a RIC transplant regimen. Classically, induction-type chemotherapy has been used which historically has been associated with mortality in the range of 10% or even higher. The advent of HMAs offers an alternative. They are well tolerated, and 40% to 50% of patients derive clinically relevant ...
While all three types can replenish a patients blood and bone marrow cells, there are advantages and disadvantages to each. The doctor will suggest the best type of stem cell for your childs illness.. The next step in the transplantation process is conditioning therapy, which kills unhealthy cells (like cancer cells) to make room for stem cells to grow and/or weakens the immune system so that theres less chance of the body rejecting the new cells.. One type of conditioning therapy delivers high doses of chemotherapy and/or radiation to kill cells, destroy the bone marrow, and weaken the immune system. Most kids will get this type of therapy. Another type of conditioning therapy delivers lower doses of chemotherapy, radiation, or another treatment to weaken the immune system. The doctor will decide which type of conditioning therapy is best.. Soon after the conditioning phase, the transplant itself will be done through intravenous (IV) infusion, and healthy stem cells will be introduced to the ...
Curr Res Transl Med. 2016 Apr-Jun;64(2):107-13. doi: 10.1016/j.retram.2016.03.004. Epub 2016 Jun 1. Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. Arruda LC1, Clave E2, Moins-Teisserenc H2, Douay C2, Farge D3, Toubert A2. Author information Abstract
Curr Res Transl Med. 2016 Apr-Jun;64(2):107-13. doi: 10.1016/j.retram.2016.03.004. Epub 2016 Jun 1. Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. Arruda LC1, Clave E2, Moins-Teisserenc H2, Douay C2, Farge D3, Toubert A2. Author information Abstract
Introduction: Cardiotoxicity is a relatively frequent and potentially serious complication of antitumor treatment. Anthracyclines and other high-dose
Schlenk, R F; Taskesen, E; van Norden, Y; Krauter, J; Ganser, A; Bullinger, L; Gaidzik, V I; Paschka, P; Corbacioglu, A; Göhring, G; Kündgen, A; Held, G; Götze, K; Vellenga, E; Kuball, J; Schanz, U; Passweg, J; Papst, T; Maertens, J; Ossenkoppele, G J; Delwel, R; Döhner, H; Cornelissen, J J; Döhner, K; Löwenberg, B (2013). The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood, 9(122):1576-1582.. Lugthart, S; Gröschel, S; Beverloo, H B; Kayser, S; Valk, P J; van Zelderen-Bhola, S L; Ossenkoppele, G J; Vellenga, E; van den Berg-de Ruiter, E; Schanz, U; Verhoef, G; Vandenberghe, P; Ferrant, A; Köhne, C H; Pfreundschuh, M; Horst, H A; Schlegelberger, H; Jotterand, M; Krauter, J; Pabst, T; Theobald, M; Schlenk, R F; Delwel, R; Döhner, K; Löwenberg, B; Döhner, H (2010). Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q ...
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.. ...
主题:BuildingRiskScoresforEvaluatingSurvivalafterHematopoieticCellTransplantationUsingPre-Tran主讲人:LuePingZhao地点:松江校区一号学院楼140报告厅时间:2018-10-2313:00:00组织单位:计算机学院主讲人简介:Dr.LuePingZhaohasreceivedhistrainingfromBiostatistics,ComputerScience,andPublicHealthSciences
The introduction of cord blood (CB) as an alternative graft source for patients without a human leukocyte antigen (HLA) matched donor was a clear breakthrough i...